

University of Groningen

In Reply to Yavas et al.

Groot, Crystal; Beukema, Jannet C; Prakken, Niek J H; Muijs, Christina T

Published in:
International Journal of Radiation Oncology, Biology, Physics

DOI:
[10.1016/j.ijrobp.2021.08.012](https://doi.org/10.1016/j.ijrobp.2021.08.012)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2021

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):
Groot, C., Beukema, J. C., Prakken, N. J. H., & Muijs, C. T. (2021). In Reply to Yavas et al. *International Journal of Radiation Oncology, Biology, Physics*, 111(5), 1323. <https://doi.org/10.1016/j.ijrobp.2021.08.012>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

In Reply to Yavas et al.



To the Editor: We thank Yavas et al for their interest in our study, their letter, and the points they raise.¹ The authors refer to the RTOG 0617 trial² in patients with non-small cell lung cancer, in which dose escalation led to more treatment-related deaths and dose-volume parameters such as heart V5 and V30 were related to this excess mortality. It is known from the literature that heart dose is associated with grade ≥ 3 cardiac events, and patients who develop cardiac complications have significantly worse overall survival.³

In our study we focused on the mean dose to left ventricular (LV) myocardial segments in relation to the mean extracellular volume (ECV) in those segments. When aiming to map and quantify myocardial fibrosis as a direct consequence of radiation dose to the heart, we believe that this is a more accurate approach than the use of volumetric parameters of the whole heart, in which the spatial information is lost. Nevertheless, we evaluated the relation between mean LV ECV and dose volume-parameters such as V5, V30, and V40. These DVH parameters of the heart highly correlate with the mean heart dose. If both study groups are included, these parameters were all statistically significantly ($P < .001$) related to the mean LV ECV, but within the nCRT group no relation was found. This might be due to the small sample size, which is less of a problem when we take all LV segments into account.

Yavas et al also raised the question of whether concurrent chemotherapy might have contributed to the effect of the radiation therapy on ECV. A dose effect relationship was seen over the entire dose range. However, even in the low-dose segments, the ECV was significantly higher than in our older control patients, which might indicate an additional effect of chemotherapy.

As stated in the paper, we agree that further research in large prospective cohorts is needed to determine the clinical relevance of developing elevated mean LV ECV after thoracic irradiation. We would like to emphasize that our patient cohort contains long-term survivors of esophageal

cancer. Because patients with cardiac toxicity have worse overall survival rates, our study design initiated a selection bias. This only strengthens our interest in a large prospective trial. How does myocardial fibrosis develop over time, and what role does this pathology play in treatment-related deaths?

Crystal Groot, MD^{1,2}
 Jannet C. Beukema, MD³
 Niek J.H. Prakken, PhD⁴
 Christina T. Muijs, PhD⁵

¹Department of Radiation Oncology
 Isala Hospital
 Zwolle, Netherlands

²Department of Radiation Oncology
 University Medical Center Groningen
 Groningen, Netherlands

³Department of Radiation Oncology
 University Medical Center Groningen
 Groningen, Netherlands

⁴Department of Radiology
 University Medical Center Groningen
 Groningen, Netherlands

⁵Department of Radiation Oncology
 University Medical Center Groningen
 Groningen, Netherlands

<https://doi.org/10.1016/j.ijrobp.2021.08.011>

References

1. Yavas G, Yavas C, Onal C. In Regard to de Groot et al. *Int J Radiat Oncol Biol Phys* 2021;111(5):1322.
2. Bradley JD, Paulus R, Komaki R, et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): A randomised, two-by-two factorial phase 3 study. *Lancet Oncol* 2015;16:187–199.
3. Wang X, Palaskas NL, Yusuf SW, et al. Incidence and onset of severe cardiac events after radiotherapy for esophageal cancer. *J Thorac Oncol* 2020;15:1682–1690.